This antibody 6F2 reacts exclusively with glial fibrillary acidic protein which is present in astrocytes in the central nervous system and Schwann cells.
GFAP
Reactivity: Human
WB, IHC, IF
Host: Rabbit
Monoclonal
unconjugated
Application Notes
Suitable for Immunoblotting and Immunohistochemistry on frozen sections andparaffin-embedded tissues. Recommended dilutions: 1/25-1/200 for Immunohistochemistry with avidin-biotinylatedhorseradish peroxidase complex (ABC) as detection reagent, and 1/100-1/1000 forImmunoblotting applications. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS, 0.09 % Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store lyophilized at 2-8 °C and reconstituted at -20 °C.
GFAP (55 kD) is selectively located in astrocytes and represents the major constituent of astrocytic intermediate filaments. GFAP expression levels are highly variable during development of the central nervous system. In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer's disease, epilepsy and multiple sclerosis. In the peripheral nervous system GFAP is expressed by Schwann cells. Upon differentiation, myelin forming Schwann cells down-regulate GFAP, whereas in non-myelin forming Schwann cells GFAP persists into adulthood.Synonyms: Glial Fibrillary Acidic Protein